PGY2 Oncology Pharmacy Resident The Ohio State University Columbus, Ohio, United States
Poster Abstract: Background. Neoadjuvant therapy (NAT) can induce disease response in some patients with pancreatic cancer with the goal of surgical resection in borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The modified FOLFIRINOX (mFOLFIRINOX) is a commonly used regimen for NAT. The dose-response relationship between chemotherapy and surgery remains unclear. This study examines the optimal dose intensity, assessed as relative dose intensity (RDI), needed to achieve the goals of NAT to determine which patients benefit most from NAT, minimize toxicities associated with NAT while maintaining efficacy, and potentially spare the need for post-operative chemotherapy.
Objectives. The primary efficacy outcome was the proportion of patients who underwent curative-intent surgery within eight months of initiation of neoadjuvant chemotherapy. Secondary efficacy outcomes included R0 resection rate, progression-free survival, overall survival, and tumor regression score. Safety outcomes included frequencies of toxicities leading to treatment discontinuation.
Methods. This retrospective observational cohort study included individuals with BRPC or LAPC who received mFOLFIRINOX as NAT between January 1, 2018, and December 31, 2022, at The Ohio State University Comprehensive Cancer Center. The relative dose intensity (RDI) of fluorouracil, irinotecan, and oxaliplatin was calculated for each patient, and a median RDI of all patients was calculated. The average of the three values determined whether patients were placed into Cohort A, in which the RDI was less than the median RDI, or Cohort B, in which the RDI was equal to or greater than the median RDI.
Results. Pending.
Discussion. Pending.
Conclusion. Pending.
References (must also be included in final poster): References
Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022;74(1):35-42. doi:10.1007/s13304-021-01186-1
Soweid AM. The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition. Endosc Ultrasound. 2017;6(Suppl 3):S76-S78. doi:10.4103/eus.eus_66_17
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163-172. doi:10.1038/nrclinonc.2009.236
Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541-2556. doi:10.1200/JCO.2016.67.5553
Versteinje E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022;40(11):1220-1230. doi: 10.1200/JCO.21.02233
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775
